title: The use of low-dose protracted oral clofarabine in a patient with myelodysplastic syndrome after failing 5-azacitidine.
abstract: Patients with myelodysplastic syndrome who fail hypomethylating agents have a very short median survival and about 25% risk of disease transformation to acute myeloid leukemia. We report our experience with low-dose protracted oral clofarabine in one patient who achieved stable disease for more than two years after failing 5-azacitidine.
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
authors.forename: Omar
authors.initials: O
authors.lastname: Al Ustwani
authors.affiliation: Clinical Research Services, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA.
authors.forename: Jessica D
authors.initials: JD
authors.lastname: Greene
authors.affiliation: Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
authors.forename: Meir
authors.initials: M
authors.lastname: Wetzler
keywords: Azacitidine; Clofarabine; Decitabine; Myelodysplastic syndrome